Novel--and "neu"--therapeutic possibilities for heart failure.
Freedman
Neil J
NJ
Ginsburg
Geoffrey S
GS
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D017209:Apoptosis; D001943:Breast Neoplasms / Q000188:drug therapy; D002303:Cardiac Output, Low / Q000188:drug therapy / Q000503:physiopathology*; D009202:Cardiomyopathies / Q000139:chemically induced / Q000503:physiopathology*; D066246:ErbB Receptors / Q000502:physiology; D006801:Humans; D051379:Mice; D032383:Myocytes, Cardiac / Q000473:pathology; D009419:Nerve Tissue Proteins / Q000502:physiology*; D020890:Neuregulin-1; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000502:physiology*; D066247:Receptor, ErbB-4; D015398:Signal Transduction; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D066246:ErbB Receptors; D009419:Nerve Tissue Proteins; D020890:Neuregulin-1; D018719:Erb-b2 Receptor Tyrosine Kinases; D066247:Receptor, ErbB-4; D000068878:Trastuzumab; C094131:NRG1 protein, human; C587689:ERBB4 protein, human; C587690:Erbb4 protein, mouse